With a specificity of 95%, CA125 achieved 100% sensitivity on the Proseek® plates when comparing sera from late stage serous ovarian cancer cases versus healthy women or women with benign ovarian disease, and 93% sensitivity when comparing sera from early stage serous ovarian cancer cases versus healthy women. Here, MUC16 is linked to ovarian serous adenocarcinoma.